Format

Send to

Choose Destination
Vaccine. 2009 Nov 5;27 Suppl 4:D28-32. doi: 10.1016/j.vaccine.2009.08.102.

Advances in the development of next-generation anthrax vaccines.

Author information

1
United States Army Medical Research Institute of Infectious Diseases, Headquarters, 1425 Porter Street, Fort Detrick, MD 21702-5011, USA. arthur.friedlander@us.army.mil

Abstract

Anthrax, a disease of herbivores, only rarely infects humans. However, the threat of using Bacillus anthracis, the causative agent, to intentionally produce disease has been the impetus for development of next-generation vaccines. Two licensed vaccines have been available for human use for several decades. These are composed of acellular culture supernatants containing the protective antigen (PA) component of the anthrax toxins. In this review we summarize the various approaches used to develop improved vaccines. These efforts have included the use of PA with newer adjuvants and delivery systems, including bacterial and viral vectors and DNA vaccines. Attempts to broaden the protection afforded by PA-based vaccines have focused on adding other B. anthracis components, including spore and capsule antigens.

PMID:
19837282
DOI:
10.1016/j.vaccine.2009.08.102
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center